文献速递妇科

III期子宫内膜癌接受辅助联合化疗与放疗的治疗顺序

Sequencing of therapy in women with stage III endometrial carcinoma receiving adjuvant combination chemotherapy and radiation.
PubMed 文献 · Gynecol Oncol · 2019-08-06

基于美国国家癌症数据库2004至2015年6981例IIIC期子宫内膜癌接受辅助化疗(CT)与体外放疗(RT)的患者,分析治疗顺序与死亡率的关系。倾向评分加权分析显示,相较先化疗后放疗,先放疗后化疗的死亡风险无差异(HR=1.01;95%CI 0.86-1.19),同步治疗与死亡风险增加47%相关(HR=1.47;95%CI 1.31-1.66)。结论认为先化疗策略与较同步治疗改善的生存相关。

要点

  • IIIC期子宫内膜癌辅助治疗中先化疗后放疗比例从2004年39.9%升至2015年75.5%。
  • 相较先化疗后放疗,同步治疗与死亡风险增加47%相关(HR=1.47;95%CI 1.31-1.66)。
  • 先放疗后化疗与先化疗后放疗相比死亡风险无差异(HR=1.01;95%CI 0.86-1.19)。

核心结论

  • 在IIIC期子宫内膜癌接受联合化疗与体外放疗的女性中,先化疗策略与较同步治疗改善的生存相关。

研究设计与样本

  • 使用美国国家癌症数据库识别2004至2015年接受辅助化疗与放疗的IIIC期子宫内膜癌女性。
  • 共识别6981例患者,按治疗顺序分为先放疗后化疗、先化疗后放疗或同步治疗。
  • 通过加权倾向评分分析检验治疗顺序与死亡率的关系。

主要发现

  • 6981例中,先化疗后放疗5116例(73.3%),先放疗后化疗696例(10.0%),同步治疗1169例(16.7%)。
  • 先化疗后放疗使用率从2004年39.9%升至2015年75.5%,先放疗后化疗从34.0%降至4.4%,同步治疗从26.1%降至20.2%(P < 0.001)。
  • 相较先化疗后放疗,先放疗后化疗死亡风险无差异(HR=1.01;95%CI 0.86-1.19)。
  • 相较先化疗后放疗,同步治疗与死亡风险增加47%相关(HR=1.47;95%CI 1.31-1.66)。
  • 敏感性分析将先放疗组(先放疗后化疗或同步放化疗)合并后,相较先化疗后放疗策略死亡风险增加25%(HR=1.25;95%CI 1.13-1.39)。

临床怎么用

  • 原文结论认为先化疗策略与较同步治疗改善的生存相关,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: While women with stage III endometrial cancer are often treated with chemotherapy and external beam radiation, the optimal sequence of these modalities is unknown. We examined the association between the sequence of chemotherapy (CT) and external beam radiation therapy (RT) on survival for women with stage IIIC endometrial carcinoma. METHODS: The National Cancer Database was used to identify women with stage IIIC endometrial carcinoma treated with adjuvant CT and RT from 2004 to 2015. Patients were stratified based on the sequence of therapy: RT before CT, CT before RT, or concurrent therapy. The association between treatment sequence and mortality was examined through a weighted propensity score analysis. RESULTS: A total of 6981 patients were identified, including 5116 (73.3%) who received CT before RT, 696 (10.0%) who received RT before CT, and 1169 (16.7%) who received concurrent therapy. The use of CT-RT increased from 39.9% in 2004 to 75.5% in 2015, while use of RT-CT decreased from 34.0% to 4.4% and concurrent therapy decreased from 26.1% to 20.2% over the same period (P < 0.001). Compared to CT-RT, there was no difference in risk of mortality with RT before CT (HR = 1.01; 95% CI, 0.86-1.19) while concurrent therapy was associated with a 47% increased risk of mortality (HR = 1.47; 95% CI, 1.31-1.66). In a sensitivity analysis combining the groups that received RT first (RT before CT or concurrent RT-CT), mortality was 25% higher (HR = 1.25; 95% CI, 1.13-1.39) compared to a strategy of CT followed by RT. CONCLUSION: Among women with stage IIIC endometrial carcinoma treated with combination chemotherapy and external beam radiation, a strategy employing chemotherapy first is associated with improved survival compared to concurrent therapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Latham AH, Chen L, Hou JY, et al. Sequencing of therapy in women with stage III endometrial carcinoma receiving adjuvant combination chemotherapy and radiation. Gynecol Oncol. 2019. PMID: 31395371. doi:10.1016/j.ygyno.2019.07.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。